GELS (Gelteq Limited) Net Profit

Corporate emblem and logo of Gelteq Limited (GELS)

Competition with industry behemoths over drug delivery methods may constrain growth, as evidenced by Gelteq Limited profit on the current GURU.Markets platform chart, where the indicator level stands at -0.01. However, Gelteq Limited is implementing robots to automate dosing in sterile zones, reducing manual labor. Business stability relies on patents for gel-based nutraceutical delivery and the expansion of licensing deals.

GELS: Gelteq Limited Net Profit 10/30/2024 - 10/30/2026

Financial and market metric breakdowns for gelteq.com (GELS)

- current quotes and average value forecast:
Market Chart Gelteq|GELS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization GELS|GELS - Total Company Value
- book capitalization data:
Net Assets per Single Share Gelteq|GELS - Book Capitalization|Market Capitalization to Book Value gelteq.com|GELS - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Equity Gelteq Limited|GELS - Long-Term Debt to Capital|Current Liabilities to Capital Gelteq|GELS - Company Aggregate Debts|Debt to Book Value Ratio GELS|GELS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Gelteq|Critical Liquidity Ratio gelteq.com
- earnings and valuation multiples information:
GELS - Net Profit
Fundamental valuation:Gelteq Limited Inc
Product sample of Gelteq Limited

This indicator measures the overall financial performance of management by tracking net income trends to assess the operational resilience of the business during periods of low price volatility. An analysis of the organization's net profit determines how successfully the patented gel encapsulation technology converts into actual cash flow through long-term B2B contracts within the specialized pharmaceutical ecosystem of Gelteq Limited (GELS).

Key competitors

VRTX - Net Financial Result|ALNY (Alnylam Pharmaceuticals) - Net Profit|Net Profit insmed.com|Company Net Income United Therapeutics Corporation (UTHR)|Company Net Income BMRN (BioMarin Pharmaceutical Inc.)|Net Profit BBIO (BridgeBio Pharma Inc)|Net Financial Result BGM Group Limited (BGM)|COGT: Net Income|Profit After Tax XERS|KROS: Net Profit|Company Net Income Arcturus Therapeutics Inc (ARCT)|ETON (Eton Pharma) - Net Profit|Company Profit KMDA (Kamada Pharma)|Net Income FULC (Fulcrum Therapeutics)|ABEO (abeonatherapeutics.com) - Final Profit|Company Net Income Mereo BioPharma Group plc MREO|PLX (Protalix BioTherapeutics Inc.) - Profit After Tax|Pliant Rx - Net Profit|Final Profit APLT (Applied Therapeutics Inc.)|RNTX: Net Profit|Aytu BioPharma (AYTU) - Net Profit|Company Net Income Chemomab Therapeutics Ltd|SRXH: Final Profit|Company Net Income Polyrizon Ltd (PLRZ)|Net Income zentaris.com AEZS|Net Profit CYTH (Cyclo Therapeutics)|Net Profit Inozyme Pharma Inc. INZY|Reneo Pharmaceuticals, Inc. - Net Profit|Annual Net Income COSCIENS Biopharma Inc (CSCI)